Biosimilars in the European Union - regulatory perspectives

ICH GCG ASEAN Training Workshop on ICH Q5C, 30-31 May 2011, Kuala Lumpur
Content

• Introduction to the European Regulatory Network
• Biosimilar regulation and concepts
• Biosimilar evolution in the European Union
• European guidelines for biosimilars
• Looking ahead/Challenges
  – Increasing complexity – biosimilar monoclonal antibodies
  – International aspects and harmonisation
• Case studies
• Conclusions
Content

• Introduction to the European Regulatory Network
  • Biosimilar regulation and concepts
  • Biosimilar evolution in the European Union
  • European guidelines for biosimilars
  • Looking ahead/Challenges
    – Increasing complexity – biosimilar monoclonal antibodies
    – International aspects and harmonisation
• Case studies
• Conclusions
Introduction

• The European Medicines Agency (EMA) is a decentralised body of the EU.

• The mission of the Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health.

• Responsible for centralised procedure and co-ordination of EU network + plays a role in stimulating innovation and research in the pharmaceutical sector.
European Union

- 500 million users of medicinal products
- 27 EU Member states
- > 40 national competent authorities
European Regulatory Network

4,500 European experts

National Competent Authorities

Committees

EMA secretariat

Working Parties
Committee for Medicinal Products for Human Use

CHMP
Chairperson: Dr. E. Abadie

max. 5 Co-opted CHMP members

+ Working parties
  - PhVig
  - Safety
  - Quality
  - Biologics
  - Patients and Consumers
  - Scientific Advice

+ Ad hoc working parties
  e.g. Biosimilar Medicinal Products Working Party
Working parties

**Biosimilar medicinal products working party**
- Established in 2005
- Face-to-face meetings 3 times per year
- Responsible for non-clinical/clinical and overarching aspects of biosimilars
- Comparability and immunogenicity aspects for all biologicals

**Biologics working party**
- Initially established in 1986
- Face-to-face meetings 11 times per year
- Quality aspects relating to biological and biotechnological medicinal products (including biosimilars)
Working parties

Working parties’ tasks include:

• Preparation and revision of guidelines
• Provide scientific input to the CHMP and Scientific Advice Working Party
• Contributing to international co-operation with other regulatory authorities
• Liaising with interested parties (e.g. briefing meetings with industry)
• Organisation of workshops and trainings (e.g. biosimilar mAbs workshop, immunogenicity workshop, assessor trainings)
Centralised Procedure

Mandatory scope:

- Medicines derived from biotechnology and other high-tech processes (including biosimilars)
- Advanced-therapy medicines
- Medicines intended for the treatment of HIV/AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions, and viral diseases
- Designated orphan medicines intended for the treatment of rare diseases.

1 Scientific Opinion
1 Commission Decision valid throughout the EU
1 Product Information translated into all official EU languages
Centralised Procedure

Pre-submission
Primary Evaluation
Clock Stop
Secondary Evaluation
Post Authorisation

D.1
D.120
D.121
D.210

LoQ
Answers
Response Assessment
Opinion
Decision

Scientific Advice
Rap/Co-Rap
Rap/Co-Rap
Day 80 Assessment Reports

-PhVig
-Variations
-Extensions
-Renewal
Content

• Introduction to the European Regulatory Network

• **Biosimilar regulation and concepts**

• Biosimilar evolution in the European Union

• European guidelines for biosimilars

• Looking ahead/Challenges
  - Increasing complexity – biosimilar monoclonal antibodies
  - International aspects and harmonisation

• Case studies

• Conclusions
What is a biosimilar?

• Previous generic definition not sufficient

• “The provisions of Article 10(1)(a)(iii) [i.e. for generic medicinal products] may not be sufficient in the case of biological medicinal products. If the information required in the case of essentially similar products (generics) does not permit the demonstration of the similar nature of two biological medicinal products, additional data, in particular, the toxicological and clinical profile shall be provided.”

• Section 4, Part II, Annex 1 (Dir. 2001/83/EC)
Biosimilars are not generics

Can we have “biogenerics”?  

In THEORY – YES  

In PRACTICE – may be possible where molecule is fully characterised (depends on complexity)  

RESULT – Similar Biological Medicinal Product, Informally: “biosimilar”
Biosimilar legislation

Legislation states:
Article 10(4) of Directive 2001/83/EC, as amended

• Where there are differences, particularly relating to raw materials or manufacturing processes of biosimilar and reference product, then results of appropriate pre-clinical tests or clinical trials relating to these conditions must be provided.

• The results of other tests and trials from the reference medicinal product’s dossier shall not be provided.
Dossier requirements for Biosimilars

<table>
<thead>
<tr>
<th>CTD Module</th>
<th>Originator</th>
<th>Biosimilar</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Quality</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Non-Clinical</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Clinical</td>
<td></td>
</tr>
</tbody>
</table>

Cross reference – class specific
Safety and Efficacy

Cross reference – product specific
Quality, Safety and Efficacy

Integrated Comparability Exercise – product specific
Quality, Safety and Efficacy
Comparability exercise

- Stepwise head-to-head comparison at the levels of quality, safety and efficacy to demonstrate that the biosimilar and the reference medicinal product have similar profiles in terms of quality, safety and efficacy.

- Depending on the similarity on the quality profile, the extent of the non-clinical and clinical testing may be reduced compared to a stand-alone development.

- Any differences in the quality attributes require a satisfactory justification of the potential implications with regard to the safety and efficacy of the product.
Content

- Introduction to the European Regulatory Network
- Biosimilar regulation and concepts
- **Biosimilar evolution in the European Union**
- European guidelines for biosimilars
- Looking ahead/Challenges
  - Increasing complexity – biosimilar monoclonal antibodies
  - International aspects and harmonisation
- Case studies
- Conclusions
Evolution of Biosimilars in the EU

**Legislation**
- Directive 2001/83/EC
- Directive 2004/27/EC

**Overarching guideline**
- Quality guideline
  - Non-clinical/Clinical guideline

**Guidance**
- Product-class specific guidelines

**Product evaluation**
- First biosimilars authorised – Omnitrope and Valtropin
- First biosimilar epoetins authorised
- First biosimilar filgrastims authorised
# Biosimilar MAA Procedures

status May 2011

<table>
<thead>
<tr>
<th></th>
<th>Product Details</th>
<th>Company</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Omnitrope (somatropin)</td>
<td>Sandoz</td>
<td>Authorised</td>
</tr>
<tr>
<td>2</td>
<td>Valtropin (somatropin)</td>
<td>Biopartners</td>
<td>Authorised</td>
</tr>
<tr>
<td>3</td>
<td>Alpheon (interferon alfa)</td>
<td>Biopartners</td>
<td>Negative</td>
</tr>
<tr>
<td>4</td>
<td>Binocrit (epoetin alfa)</td>
<td>Sandoz</td>
<td>Authorised</td>
</tr>
<tr>
<td>5</td>
<td>Epoetin alfa Hexal (epoetin alfa)</td>
<td>Hexal</td>
<td>Authorised</td>
</tr>
<tr>
<td>6</td>
<td>Abseamed (epoetin alfa)</td>
<td>Medice</td>
<td>Authorised</td>
</tr>
<tr>
<td>7</td>
<td>Silapo (epoetin zeta)</td>
<td>Stada</td>
<td>Authorised</td>
</tr>
<tr>
<td>8</td>
<td>Retacrit (epoetin zeta)</td>
<td>Hospira</td>
<td>Authorised</td>
</tr>
<tr>
<td>9</td>
<td>Insulin Marvel Short (human insulin)</td>
<td>Marvel Life Sciences</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>10</td>
<td>Insulin Marvel Intermediate (human insulin)</td>
<td>Marvel Life Sciences</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>11</td>
<td>Insulin Marvel Long (human insulin)</td>
<td>Marvel Life Sciences</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>12</td>
<td>Filgrastim Ratiopharm (filgrastim)</td>
<td>Ratiopharm</td>
<td>Authorised</td>
</tr>
<tr>
<td>13</td>
<td>Ratiograstim (filgrastim)</td>
<td>Ratiopharm</td>
<td>Authorised</td>
</tr>
<tr>
<td>14</td>
<td>Biograstim (filgrastim)</td>
<td>CT Arzneimittel</td>
<td>Authorised</td>
</tr>
<tr>
<td>15</td>
<td>Tevagrastim (filgrastim)</td>
<td>Teva</td>
<td>Authorised</td>
</tr>
<tr>
<td>16</td>
<td>Filgrastim Hexal (filgrastim)</td>
<td>Hexal</td>
<td>Authorised</td>
</tr>
<tr>
<td>17</td>
<td>Zarzio (filgrastim)</td>
<td>Sandoz</td>
<td>Authorised</td>
</tr>
<tr>
<td>18</td>
<td>Nivestim (filgrastim)</td>
<td>Hospira</td>
<td>Authorised</td>
</tr>
<tr>
<td>19</td>
<td>Epostim (epoetin alfa)</td>
<td>Reliance Genemedix</td>
<td>Withdrawn</td>
</tr>
</tbody>
</table>
Scientific Advice

Scientific Advice for Biosimilars

Number of applications

Follow-up advice
First advice

2003 2004 2005 2006 2007 2008 2009 2010
Content

- Introduction to the European Regulatory Network
- Biosimilar regulation and concepts
- Biosimilar evolution in the European Union
- **European guidelines for biosimilars**
- Looking ahead/Challenges
  - Increasing complexity – biosimilar monoclonal antibodies
  - International aspects and harmonisation
- Case studies
- Conclusions
Guidelines for biosimilars

Overarching Guideline (CHMP/437/04).
“Guideline on Similar Biological Medicinal Products”

Quality

Non-clinical
Clinical

General guidelines
Quality / Safety
Efficacy

Product class
specific data requirements

Insulin
Somatropin
GCSF
Epoetin
LMMH
IFN-α

Non-clinical
Non-clinical
Non-clinical
Non-clinical
Non-clinical
Non-clinical

Clinical
Clinical
Clinical
Clinical
Clinical
Clinical

Under development:
mAbs
Follitropin alfa
IFN-β
Overarching guideline

Guideline on similar biological medicinal products (CHMP/437/04)

- **Scope**
  - In principle: biosimilar concept applicable to any biological medicinal product.
  - In practice: Only for products that can be thoroughly characterised.

- Biosimilarity should be established at all levels (Q/S/E) using a reference medicinal product authorised in the Community on the basis of a complete dossier.

- Active substance should be similar to the reference medicinal product in molecular and biological terms.

- The pharmaceutical form, strength and route of administration should be the same as for the reference.

- The specific medicinal product given to the patient should be identified in order to support pharmacovigilance monitoring.
Quality guideline

Scope:
- Applies to recombinant DNA derived proteins and peptides

Manufacturing process:
- Use state of the art process development
- Use material from final process for clinical trials (i.e. avoid additional comparability exercises)
- The suitability of the formulation should be demonstrated

Comparability exercise:
- Use state-of-art analytical methods for characterisation of both biosimilar and reference medicinal product
- Comparative characterisation studies should include assessment of composition, physical properties, primary and higher order structures, purity, product-related isoforms and impurities, and biological activity
- Comparability both at level of medicinal product and active substance
Non-clinical / Clinical guideline

Non-clinical studies:

- Comparative in nature; designed to detect differences
- *In vivo* studies should be conducted in relevant species
  - Pharmacodynamic study + at least one repeat dose toxicity study

Clinical studies:

- Comparative pharmacokinetics (PK) and pharmacodynamics (PD) studies are requested
- In certain cases, comparative PK/PD studies might be sufficient to demonstrate clinical comparability, but usually comparative efficacy trials are required
- Pre-licensing safety data in patients should be obtained
- One year follow-up data on immunogenicity usually required pre-licensing for long term treatment
Non-clinical / Clinical guideline

Pharmacovigilance/Risk management:

- Risk Management Plan and Pharmacovigilance system must be in place, in accordance with EU legislation
- Any safety monitoring imposed on the reference product or product class should be considered in the RMP

Indication(s):

- Each claimed indication should be justified or demonstrated separately
- Extrapolation is possible, but depends on clinical experience, available literature data, same mechanisms of action or receptor(s) involved in all indications
Revision of guidelines

- In light of additional experience, guidelines are revised if necessary.

- Revision of epoetin guideline (2008-2010)
  - Amended to accept extrapolation of efficacy data from one route of administration to the other via bridging studies (PK/PD studies)

- Revision of quality guideline initiated (concept paper published for comments until 31 May)
  - Include considerations for product lifecycle (e.g. change in reference product during biosimilar development, post-authorisation activities)

- Need for revision of LMWHs guideline?
  - Potential revision to increase flexibility in clinical data requirements: consider extent of quality characterisation
Content

- Introduction to the European Regulatory Network
- Biosimilar regulation and concepts
- Biosimilar evolution in the European Union
- European guidelines for biosimilars
- **Looking ahead/Challenges**
  - Increasing complexity – biosimilar monoclonal antibodies
  - International aspects and harmonisation
- Case studies
- Conclusions
Increasing complexity

Current situation:
• Biosimilars currently licensed are “small biologicals”
• Biosimilar framework exists for more complex products

Ongoing:
• High interest in biosimilar monoclonal antibodies
  – Scientific advice
  – Workshop organised by the Agency in July 2009
  – Guideline under development

Future:
• In principle, the concept applies to any biological medicine
• Ability to characterise becomes critical
• How far can we go?
Spectrum of complexity

- **Aspirin**
  - MW: 0.2 kDa

- **IFN alfa**
  - 165AA, MW: 19 kDa

- **IgG**
  - ~1300AA, MW: ~150 kDa

- **FVIII**
  - ~2330AA, MW: ~330 kDa

- **Virus like particle**
  - MW: ~20 000 kDa

**Chemicals**

**Recombinant DNA technology**

**Blood-derived**

**Immunologicals**

**Advanced therapy**

Source: Dr Kowid Ho (Afssaps, France)
Biosimilar Monoclonal Antibodies?

**PHYSICOCHEMICAL CHARACTERISTICS**

**VARIABLE REGION**
- Deamidation
- Oxidation
- N-term Pyro-Glu
- Glycosylation
- Glycation

**CONSTANT REGION**
- Deamidation
- Oxidation
- Acetylation
- Glycation
- Glycosylation (fucosylation, sialylation, galactosylation, mannosylation...)
- C-term Lys
- Disulphide bond shuffling/cleavage
- Fragmentation/clipping

**BIOLOGICAL CHARACTERISTICS**

**BINDING**
- Affinity
- Avidity
- Immunoreactivity/crossreactivity
- Unintentional reactivity

**EFFECTOR FUNCTION**
- Complement interaction
- FcRn, FcyR interaction
- Mannan binding ligand interaction
- Mannose receptor interaction

**OTHER BIOLOGICAL PROPERTIES**
- PK properties
- Epitope/Immunogenicity
- Modulatory region (Tregitope...)

...
Biosimilar Monoclonal Antibodies?

- Monoclonal antibodies are complex molecules
  - High level of microheterogeneity, there will always be differences
  - The mode of action is complex and may involve contributions from multiple mechanisms

- The challenge: to demonstrate that differences between the biosimilar and the reference medicinal product do not have a significant impact on clinical efficacy and/or safety
  - Even small differences may have significant effects.
  - Need to combine physicochemical results with functional assays (e.g. antigen-antibody binding assays and cell-based assays) and the qualification in preclinical and clinical studies
Scientific Advice for biosimilar monoclonal antibodies

Scientific advice for biosimilar mAbs

Number of applications

2008 2009 2010
Draft guideline on biosimilar mAbs
(EMA/CHMP/BMWP/403543/2010)

- For public consultation until 31 May 2011 -

Scope:
• Non-clinical and clinical data requirements for biosimilar monoclonal antibodies. Principles may also apply to certain fusion proteins (-cept molecules).

Non-clinical:
• A risk-based approach to evaluate mAb on a case-by-case basis is recommended to decide on the choice and extent of in vitro and particularly in vivo studies.

PK/PD:
• Comparative pharmacokinetic study in a sufficiently sensitive and homogeneous study population (healthy volunteers or patients)
• Pharmacokinetic data can be helpful to extrapolate data on efficacy and safety between different clinical indications
• PD studies, if feasible, can provide strong support for biosimilarity
Draft guideline on biosimilar mAbs
(EMA/CHMP/BMWP/403543/2010)

Safety/Efficacy:
• Should normally be demonstrated through a phase III equivalence trial
• Trial designed to demonstrate similar efficacy and safety compared to the reference product, not patient benefit per se
• Choose most sensitive population
• Extrapolation of indications possible based on overall evidence of biosimilarity

RMP and PhVig plan:
• Required as for all biosimilars
• Post authorisation safety studies may be required
Content

- Introduction to the European Regulatory Network
- Biosimilar regulation and concepts
- Biosimilar evolution in the European Union
- European guidelines for biosimilarx

- **Looking ahead/Challenges**
  - Increasing complexity – biosimilar monoclonal antibodies
  - *International aspects and harmonisation*

- Case studies

- Conclusions
Biosimilars - International Cooperation

The European Medicines Agency is liaising with international partners

- **Health Canada** (finalised Guidance on Subsequent Entry Biologics published in March 2010)
- **Japan** (Guideline on quality, safety and efficacy of follow-on biologics was published in March 2009)
- **WHO** (Guidelines on Evaluation of Similar Biotherapeutic Products adopted in October 2009)
- **FDA** (Abbreviated approval pathway for Biosimilars created via the Patient Protection and Affordable Care Act, signed on March 23, 2010) - ongoing liaison and exchange

**CHMP guidance also adopted by, e.g.:**
- Australia
- Malaysia

→ EU experience important reference for others
Global development of biosimilars?

- Directive 2001/83/EC states that the chosen reference medicinal product must be a medicinal product authorised in the Community.

- The set-up of the biosimilar development is not specified in the Directive. However, the implementing guidelines state that the reference medicinal product authorised in the Community should be used throughout the development.

- Can requirements for the sourcing of reference product evolve to allow for parts of the comparability exercise to be performed with reference medicinal product sourced outside the Community?
Traceability

- Trade name and batch number of biological products (including biosimilars) should be included in adverse reaction reporting
  - Notice to Applicants Vol.9 (2008)
  - Directive 2010/84/EU (December 2010)
- INN important factor, responsibility of WHO
- Interchangeability/substitution is not covered by EU pharmaceutical legislation – outside remit of EMA (responsibility of the individual member states)
Content

- Introduction to the European Regulatory Network
- Biosimilar regulation and concepts
- Biosimilar evolution in the European Union
- European guidelines for biosimilars
- Looking ahead/Challenges
  - Increasing complexity – biosimilar monoclonal antibodies
  - International aspects and harmonisation
- **Case studies**
- Conclusions
Case studies
Omnitrope (somatropin)

- Reference medicinal product: Genotropin
- Changes during development (active substance manufacturer). Increase in complexity of demonstration of comparability
- Additional steps introduced to reduce levels of Host Cell Protein
- Very high levels of (non-neutralising) antibodies, up to ~ 60% (for material used in clinical trials – manufactured according to old process)
- Additional liquid formulations added in the post-authorisation phase, posology unchanged
Valtropin (somatropin)

- Reference medicinal product: Humatrope

- Different expression system compared to reference medicinal product (*S. Cerevisiae* vs *E.coli*). Process specific HCP (yeast) assay required

- Changes during development subject to additional comparability

- Clinical trial:
  - initially calculated to demonstrate non-inferiority
  - US sourced reference product used (considered supportive)

- Indications differ from Omnitrope (Different reference medicinal product used)
  - Paediatric indications for Omnitrope only: Small Gestational Age (SGA), Prader-Willi Syndrome (PWS)
**Binocrit (epoetin alfa)**

- Reference medicinal product: Erypo/Eprex (epoetin alfa)

- Extensive characterisation and quality comparability exercise

- Structural comparisons
  - Qualitatively similar
  - Quantitative differences seen (Increase in high mannose-6-phosphate, Decrease in N-glycolyl-neuraminic acid)
  - Differences were justified

- PRCA (Pure Red Cell Aplasia) issue with Reference medicinal product
  - Subcutaneous (SC) route contraindicated (chronic kidney disease, CKD patients) until May 2006
  - SC route most sensitive for potential immunogenicity
  - Consequence: No comparative SC studies (CKD)
  - SC route in immunocompetent individuals contraindicated for biosimilar (further studies needed)
  - Risk minimisation required to avoid off-label SC use
Silapo (epoetin zeta)

- Reference medicinal product: Erypo/Eprex (epoetin alfa)

- Extensive characterisation and quality comparability exercise

- Structural comparisons
  - Qualitatively similar
  - Quantitative differences seen (Increase in des o-glycan forms, Decrease in N-glycolyl-neuraminic acid)
  - Differences were justified

- SC route initially contraindicated as for Binocrit. SC indications added post-authorisation upon availability of data
**Tevagrasit (filgrastim)**

- Reference medicinal product: Neupogen
- Extensive characterisation and quality comparability exercise
- Partial use of reference medicinal product sourced in Lithuania before EU accession – could only be considered supportive data
- Clinical data
  - Phase I: Comparative PK/PD studies in healthy volunteers
  - Phase III: Comparative Safety & Efficacy trials in cancer patients undergoing chemotherapy. Efficacy endpoint: duration of severe neutropenia
Zarzio (filgrastim)

- Reference medicinal product: Neupogen

- Extensive characterisation and quality comparability exercise

- Clinical data
  - Phase I: Comparative PK/PD studies in healthy volunteers. Efficacy endpoints: neutrophil and CD34+ cell counts
  - Phase III: Non-comparative (single arm) clinical trial in cancer patients undergoing chemotherapy. Safety focus. Only supportive

- The G-CSF Guideline states:
  - “The recommended clinical model for the demonstration of comparability of the test and the reference medicinal product is the prophylaxis of severe neutropenia after cytotoxic chemotherapy in a homogenous patient group (...). Alternative models, including pharmacodynamic studies in healthy volunteers, may be pursued for the demonstration of comparability if justified.”
Reference medicinal product: Humulin S

Three presentations: Short, intermediate (30/70), long acting

Quality issues
- Incomplete comparability exercise, particularly for drug product
- Inadequate validation of manufacturing process
- Batch traceability missing
- More data required for extended release forms

Clinical issues
- Comparative PK & PD: euglycaemic clamp – most sensitive model
- Similar PK parameters, however not similar PD profiles: faster absorption (glucose infusion rate). Risk of hypoglycaemia (potentially 45% increase in glucose lowering)
- Applicant resorted to efficacy trial with HbA1C end-point, not sufficiently sensitive
- Limited immunogenicity data
Negative opinion – **Alpheon** (rhIFNα-2a)

- Reference medicinal product: Roferon-A

- Quality issues
  - Concerns regarding stability and impurities for drug substance and drug product. Profiles also not matching reference medicinal product
  - Drug product manufacturing process inadequately validated
  - Comparability between batches used for clinical trial batches and commercial batches not shown

- Non-clinical studies were inadequate and indicated differences

- Clinical issues
  - Difference in virological relapse rates
  - Inconclusive data in the response rate for the “difficult-to-treat” genotype 1 patients
  - Different rate of adverse events
  - Inadequate immunogenicity documentation
Risk management plan

- Risk Management Plan (RMP) and Pharmacovigilance system must be in place, in accordance with EU legislation.

- The RMP should include:
  - **Safety specification** *(identify safety concerns)*
  - **Pharmacovigilance plan** *(planned PhVig actions for all identified safety concerns)*
  - **Evaluation of the need for risk minimisation activities** *(routine vs additional risk minimisation activities)*
  - **Risk Minimisation Plan** *(if additional risk minimisation activities are required)*
  - **Summary of the EU-RMP**
  - **Contact person details**

- Any safety monitoring imposed on the reference product or product class should be considered in the RMP.
# RMP summary example - Binocrit

<table>
<thead>
<tr>
<th>Safety issue</th>
<th>Proposed pharmacovigilance activities</th>
<th>Proposed risk minimisation activities</th>
</tr>
</thead>
</table>
| Pure Red Cell Aplasia (PRCA) | • Routine pharmacovigilance  
• Post-authorisation safety study INJ-14  
• Phase 3 study INJ-17 | • Contraindication in section 4.3 of the SPC for use in patients who have previously experience PRCA following treatment with erythropoetins  
• Warning in section 4.4 of the SPC regarding PRCA  
• Mention in section 4.8 of the SPC |
| Increased risk of PRCA with off-label subcutaneous administration in renal failure patients | • Routine pharmacovigilance  
• Phase III study INJ-17  
• Market survey to monitor potential off-label s.c. use in renal anaemia patients | • Advice to use i.v. route only in treatment of renal anaemia, in Section 4.2 of the SPC.  
• Warning in section 4.4 of the SPC that i.v route only should be used in chronic renal anaemia patients due to lack of immunogenicity data  
**Additional measures to avoid s.c. use in renal anaemia patients**  
• Educational leaflet  
• Cool boxes with visual label |
RMP summary example - Binocrit

<table>
<thead>
<tr>
<th>Safety issue</th>
<th>Proposed pharmacovigilance activities</th>
<th>Proposed risk minimisation activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombotic vascular events (TVE)</td>
<td>• Routine pharmacovigilance</td>
<td>• Risk of thrombotic vascular events (TVE) including serious and life threatening cardio-vascular complications including the dose recommendation that the target haemoglobin not exceed 12 g/dl are mentioned in Sections 4.1, 4.2, 4.3, 4.4 and 4.8 of the SPC.</td>
</tr>
<tr>
<td></td>
<td>• Post-authorisation safety study INJ-14</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Phase 3 study INJ-17</td>
<td></td>
</tr>
<tr>
<td>Tumour Growth Potential</td>
<td>• Routine pharmacovigilance</td>
<td>• Risk of tumour growth potential are mentioned in Sections 4.4 and 5.1 of the SPC.</td>
</tr>
<tr>
<td></td>
<td>• Post-authorisation safety study INJ-14</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Phase 3 study INJ-17</td>
<td></td>
</tr>
</tbody>
</table>
Any class-effect applies across all products!

European Medicines Agency to review the safety of somatropin-containing medicines

The European Medicines Agency is starting a review of the safety of somatropin-containing medicines authorised centrally or by national procedures in the European Union (EU). The review will look into all available data on somatropin to reassess the benefit-risk balance of these medicines.

This review is being initiated further to information received from the French medicines agency on a long-term epidemiological study in patients treated during childhood with somatropin-containing medicines. The study results suggest an increased risk of mortality with somatropin therapy compared to the general population. The risk appears to be particularly increased when high doses are used (beyond doses as recommended in the Summary of Product Characteristics). The study looked at patients treated during childhood for growth hormone deficiency or short stature of unknown cause. Based on this observational study alone, the risk...

Related information:
- Nutropin AQ: EPAR
- Omnitrope: EPAR
- Valtropin: EPAR

Contact point:
Monika Benstedter or Sabine Haubenraisser
Tel. +44 (0)20 7418 8427
E-mail: press@ema.europa.eu
Content

- Introduction to the European Regulatory Network
- Biosimilar regulation and concepts
- Biosimilar evolution in the European Union
- European guidelines for biosimilars
- Looking ahead/Challenges
  - Increasing complexity – biosimilar monoclonal antibodies
  - International aspects and harmonisation
- Case studies

- Conclusions
Conclusions

• EU biosimilar portfolio and related guidelines continue to grow
• EU experience important reference for others
• Challenges for the future:
  – Moving towards more complex biosimilars, such as mAbs
  – Consider the possibility of a global development of biosimilars
EMA website:

Biosimilar medicines

A similar biological or ‘biosimilar’ medicine is a biological medicine that is similar to another biological medicine (the biological reference medicine) that has already been authorised for use. Biological medicines are made by a living organism, such as a bacterium or yeast, and can consist of relatively small molecules such as human insulin or erythropoietin or complex molecules such as monoclonal antibodies.

Biosimilars can only be authorised for use once the period of data exclusivity on the biological reference medicine has expired. In general, this means that the biological reference medicine must have been authorised for at least 10 years before a similar biological medicine can be made available by another company.

Role of the Agency

The Agency is responsible for assessing applications from companies to market biological medicines for use in the European Union (EU), including biosimilar medicines.

For biosimilar medicines, the company needs to carry out studies to show that the biosimilar is similar to the reference medicine and does not have any meaningful differences in terms of quality, safety or efficacy. As information on the reference medicine is already available, the amount of information on safety and efficacy needed in order to recommend a biosimilar for authorisation is usually less than the amount needed to authorise an original biological medicine.

As with all medicines, the Agency continues to monitor the safety of biosimilar medicines once they are on the market.

- For more information, see the scientific guidelines on biosimilar medicines.

Draft guidelines on biosimilar monoclonal antibodies and immunogenicity

On 26 November 2010, the Agency published a draft guideline on similar biological medicinal products containing monoclonal antibodies for public consultation until 31 May 2011. The guideline lays down the requirements for medicines containing monoclonal antibodies that claim to be similar to another such medicine that is already marketed.

- For more information, see the draft guideline on similar biological medicinal products containing monoclonal antibodies.

A draft guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use has also been released for public consultation until 31 May 2011.

Documents of interest

<table>
<thead>
<tr>
<th>Document(s)</th>
<th>Language</th>
<th>Status</th>
<th>First published</th>
<th>Last updated</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Questions and answers on biosimilar medicines</td>
<td>EN English</td>
<td>GO</td>
<td>30/10/2008</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Further reading

EMEA Website:
http://www.ema.europa.eu

- European Public Assessment Reports (EPARs):

- Biosimilar Guidelines:

- Directive 2001/83/EC, as amended:
Thank you for your attention

ACKNOWLEDGEMENTS:

Klara Tiitso - EMA – Sci. administrator - Quality of medicines sector (Bio)

Christian Schneider - PEI - Chairman of EMA Biosimilars WP

Peter Richardson - EMA – Section Head Biologicals - Quality of medicines sector

b.brake@bfarm.de & alberto.ganan@ema.europa.eu